Objective: To analyze the clinical value of real-time PCR for virus detection in the diagnosis and treatment of patients after allo-HSCT who had no infection evidence of pneumonia using routine pathogen detection panel. Methods: The clinical data of 71 episodes with acute lung injury from May 2015 to March 2017 after allo-HSCT in hematology department of Peking University People's Hospital (PKUPH) were retrospectively analyzed. PCR for virus detection and other routine pathogen detection tests were performed on bronchoalveolar lavage fluid (BALF) samples. Results: Among 71 episodes with acute lung injury, a total of 15 patients were diagnosed as lower respiratory tract disease merely associated with virus (detection rate of 21.13%) , 19 episodes were absent of lower respiratory tract infection. The median time from allo-HSCT to the occurrence of lung injury were 176 (49-1 376) d and 196 (57-457) d respectively (z=-0.191, P=0.864) . There were no statistical differences for baseline characteristics and clinical features between two groups. The 100-day attributable mortalities were 13.3% (2/15) and 26.3% (5/19) (χ(2)=0.864, P=0.426) . Patients with low-dose steroids treatment had favorable outcome than those with high-dose steroids treatment (the dose of methylprednisolone ≥250 mg/d as standard) [4.2% (1/24) vs 60.0% (6/10) ]. In patients with detectable virus in BALF, 2 patients died with early high-dose steroids treatment, while 11 patients survived with no steroids treatment or late application. Conclusions: Virus infection should be considered in post-HSCT pneumonia patient with negative result using routine pathogen detection panel. Expanding virus detection panel by PCR in BALF could increase diagnostic precision and might be instructive to treatment.
Objective: To analyze the clinical value of real-time PCR for virus detection in the diagnosis and treatment of patients after allo-HSCT who had no infection evidence of pneumonia using routine pathogen detection panel. Methods: The clinical data of 71 episodes with acute lung injury from May 2015 to March 2017 after allo-HSCT in hematology department of Peking University People's Hospital (PKUPH) were retrospectively analyzed. PCR for virus detection and other routine pathogen detection tests were performed on bronchoalveolar lavage fluid (BALF) samples. Results: Among 71 episodes with acute lung injury, a total of 15 patients were diagnosed as lower respiratory tract disease merely associated with virus (detection rate of 21.13%) , 19 episodes were absent of lower respiratory tract infection. The median time from allo-HSCT to the occurrence of lung injury were 176 (49-1 376) d and 196 (57-457) d respectively (z=-0.191, P=0.864) . There were no statistical differences for baseline characteristics and clinical features between two groups. The 100-day attributable mortalities were 13.3% (2/15) and 26.3% (5/19) (χ(2)=0.864, P=0.426) . Patients with low-dose steroids treatment had favorable outcome than those with high-dose steroids treatment (the dose of methylprednisolone ≥250 mg/d as standard) [4.2% (1/24) vs 60.0% (6/10) ]. In patients with detectable virus in BALF, 2 patients died with early high-dose steroids treatment, while 11 patients survived with no steroids treatment or late application. Conclusions: Virus infection should be considered in post-HSCT pneumoniapatient with negative result using routine pathogen detection panel. Expanding virus detection panel by PCR in BALF could increase diagnostic precision and might be instructive to treatment.
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Sachiko Seo; Christian Renaud; Jane M Kuypers; Charles Y Chiu; Meei-Li Huang; Erik Samayoa; Hu Xie; Guixia Yu; Cynthia E Fisher; Ted A Gooley; Steven Miller; Robert C Hackman; David Myerson; Ruth H Sedlak; Yae-Jean Kim; Takahiro Fukuda; David N Fredricks; David K Madtes; Keith R Jerome; Michael Boeckh Journal: Blood Date: 2015-04-27 Impact factor: 22.113
Authors: Daniel Couriel; Paul A Carpenter; Corey Cutler; Javier Bolaños-Meade; Nathaniel S Treister; Juan Gea-Banacloche; Paul Shaughnessy; Sharon Hymes; Stella Kim; Alan S Wayne; Jason W Chien; Joyce Neumann; Sandra Mitchell; Karen Syrjala; Carina K Moravec; Linda Abramovitz; Jerry Liebermann; Ann Berger; Lynn Gerber; Mary Schubert; Alexandra H Filipovich; Daniel Weisdorf; Mark M Schubert; Howard Shulman; Kirk Schultz; Barbara Mittelman; Steven Pavletic; Georgia B Vogelsang; Paul J Martin; Stephanie J Lee; Mary E D Flowers Journal: Biol Blood Marrow Transplant Date: 2006-04 Impact factor: 5.742
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Christian Renaud; Hu Xie; Sachiko Seo; Jane Kuypers; Anne Cent; Lawrence Corey; Wendy Leisenring; Michael Boeckh; Janet A Englund Journal: Biol Blood Marrow Transplant Date: 2013-05-13 Impact factor: 5.742
Authors: Alpana Waghmare; Angela P Campbell; Hu Xie; Sachiko Seo; Jane Kuypers; Wendy Leisenring; Keith R Jerome; Janet A Englund; Michael Boeckh Journal: Clin Infect Dis Date: 2013-09-24 Impact factor: 9.079
Authors: Sachiko Seo; Hu Xie; Angela P Campbell; Jane M Kuypers; Wendy M Leisenring; Janet A Englund; Michael Boeckh Journal: Clin Infect Dis Date: 2014-03-05 Impact factor: 9.079